Tag
This phase 3 trial shows that tarlatamab combined with durvalumab significantly improves overall and progression-free survival compared to durvalumab alone as maintenance therapy post-first-line chemoimmunotherapy in extensive-stage small-c
This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
This review synthesizes evidence on tarlatamab plus PD-L1 inhibitors as maintenance therapy post chemo-immunotherapy in extensive-stage SCLC, highlighting safety, clinical activity, and translational implications from the DeLLphi-303 study
Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.
